High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Diabetes

Does the high-dose inactivated influenza vaccine (HD-IIV) provide superior protection against severe respiratory and cardiovascular outcomes in older adults compared with the standard-dose inactivated influenza vaccine (SD-IIV), and does relative vaccine effectiveness differ among older adults with and without diabetes?In this prespecified secondary analysis of the DANFLU-2 randomized clinical trial of 332 438 older adults, including 43 881 with diabetes, HD-IIV was associated with reduced cardiorespiratory, cardiovascular, heart failure, influenza, and laboratory-confirmed hospitalizations compared with SD-IIV, irrespective of diabetes status.The trial results suggest that HD-IIV may offer incremental protection compared with SD-IIV against cardiovascular and influenza-related outcomes in individuals with and without diabetes, although these findings are exploratory and must be interpreted in this context.

Corresponding Author: Tor Biering-Sørensen, MD, MSc, MPH, PhD, Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital–Herlev and Gentofte, Gentofte Hospitalsvej 8, 3.th., 2900 Hellerup, Denmark (tor.biering@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.